...
首页> 外文期刊>BMC Cancer >Targeted next generation sequencing of RB1 gene for the molecular diagnosis of Retinoblastoma
【24h】

Targeted next generation sequencing of RB1 gene for the molecular diagnosis of Retinoblastoma

机译:RB1基因的靶向下一代测序用于视网膜母细胞瘤的分子诊断

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The spectrum of RB1 gene mutations in Retinoblastoma (RB) patients and the necessity of multiple traditional methods for complete variant analysis make the molecular diagnosis a cumbersome, labor-intensive and time-consuming process. Here, we have used targeted next generation sequencing (NGS) approach with in-house analysis pipeline to explore its potential for the molecular diagnosis of RB. Methods Thirty-three patients with RB and their family members were selected randomly. DNA from patient blood and/or tumor was used for RB1 gene targeted sequencing. The raw reads were obtained from Illumina Miseq. An in-house bioinformatics pipeline was developed to detect both single nucleotide variants (SNVs) and small insertions/deletions (InDels) and to distinguish between somatic and germline mutations. In addition, ExomeCNV and Cn. MOPS were used to detect copy number variations (CNVs). The pathogenic variants were identified with stringent criteria, and were further confirmed by conventional methods and cosegregation in families. Results Using our approach, an array of pathogenic variants including SNVs, InDels and CNVs were detected in 85% of patients. Among the variants detected, 63% were germline and 37% were somatic. Interestingly, nine novel pathogenic variants (33%) were also detected in our study. Conclusions We demonstrated for the first time that targeted NGS is an efficient approach for the identification of wide spectrum of pathogenic variants in RB patients. This study is helpful for the molecular diagnosis of RB in a comprehensive and time-efficient manner.
机译:背景技术视网膜母细胞瘤(RB)患者中RB1基因突变的频谱以及采用多种传统方法进行完整变异分析的必要性使分子诊断成为一个繁琐,费力且耗时的过程。在这里,我们将靶向下一代测序(NGS)方法与内部分析流程一起使用,以探索其在RB分子诊断中的潜力。方法随机抽取33例RB患者及其家属。来自患者血液和/或肿瘤的DNA用于RB1基因靶向测序。原始读数获自Illumina Miseq。开发了一个内部生物信息学管道,以检测单核苷酸变体(SNV)和小的插入/缺失(InDels)并区分体细胞和种系突变。此外,ExomeCNV和Cn。 MOPS用于检测拷贝数变异(CNV)。通过严格的标准鉴定病原体,并通过常规方法和家族共分离进一步证实。结果使用我们的方法,在85%的患者中检测到了一系列致病性变体,包括SNV,InDels和CNV。在检测到的变异中,种系占63%,体细胞占37%。有趣的是,在我们的研究中还发现了九种新的致病变体(33%)。结论我们首次证明靶向NGS是鉴定RB患者广泛的致病变异的有效方法。这项研究有助于全面,高效地进行RB的分子诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号